InvestSMART

CSL Limited (ASX: CSL) - Announcements

Current share price for CSL : $180.720 2.42 (1.36%)+

ASX company news and announcements for CSL Limited (CSL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All CSL Limited (CSL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than CSL Limited (CSL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for CSL Limited (CSL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$86,725 Gardasil Cross Protection Data 18 Apr 2007 9:59AM $84.200 $180.720 risen by 114.63%
$86,725 Half Yearly Report/Half Year Accounts 21 Feb 2007 8:27AM $77.420 $180.720 risen by 133.43%
$86,725 Secures long term supply of Helixate from Bayer 2 Feb 2007 8:59AM $70.500 $180.720 risen by 156.34%
$86,725 Strong trading conditions in international plasma therapies 13 Dec 2006 9:30AM $62.750 $180.720 risen by 188%
$86,725 Welcomes Federal Government Decision on Gardasil 29 Nov 2006 11:37AM $59.000 $180.720 risen by 206.31%
$86,725 Zenyth Option Scheme of Arrangement approved by Court 17 Nov 2006 4:10PM $58.070 $180.720 risen by 211.21%
$86,725 Acquisition of CytoGam from MedImmune 9 Nov 2006 9:24AM $56.910 $180.720 risen by 217.55%
$86,725 Cervical Cancer Vaccination Funding for Aust. Girls Rejected 8 Nov 2006 3:30PM $56.010 $180.720 risen by 222.66%
$86,725 CCE ann: CSL Supply Agreement 28 Sep 2006 8:42AM $53.600 $180.720 risen by 237.16%
$86,725 Preliminary Final Report/Full Year Accounts/Presentation 23 Aug 2006 8:30AM $49.500 $180.720 risen by 265.09%
$86,725 US FDA approves Mercks Gardasil 9 Jun 2006 8:49AM $52.250 $180.720 risen by 245.88%
$86,725 Half Yearly Report & Half Year Accounts 22 Feb 2006 8:30AM $51.500 $180.720 risen by 250.91%
$86,725 To apply for license to market influenza in the US 8 Feb 2006 8:29AM $46.200 $180.720 risen by 291.17%
$86,725 Application for Licensure of Gardasil by Merck & Co Inc 6 Dec 2005 8:35AM $40.850 $180.720 risen by 342.40%
$86,725 Chairman's Address & Managing Director's Presentation 12 Oct 2005 10:08AM $37.440 $180.720 risen by 382.69%
$86,725 Vaccine prevented 100% high grade cervical cancers 7 Oct 2005 8:47AM $37.460 $180.720 risen by 382.43%
$86,725 Completion of On-MktBuy-Back/Daily&FinalSharebuy-backnotices 20 Sep 2005 9:14AM $36.350 $180.720 risen by 397.17%
$86,725 2004-05 Annual Results 24 Aug 2005 8:30AM $34.980 $180.720 risen by 416.64%
$86,725 Share Buy Back 28 Jun 2005 9:16AM $34.590 $180.720 risen by 422.46%
$86,725 Share Buy Back 28 Jun 2005 9:16AM $34.590 $180.720 risen by 422.46%
$86,725 Daily Share Buy-Back Notice 28 Jun 2005 9:05AM $34.590 $180.720 risen by 422.46%
$86,725 Record Date 24 Feb 2005 4:15PM $32.100 $180.720 risen by 462.99%
$86,725 App 3C - Buy-back 23 Feb 2005 9:16AM $31.990 $180.720 risen by 464.93%
$86,725 CSL & Merck & Co Inc enter into arrangement 3 Feb 2005 8:40AM $32.350 $180.720 risen by 458.64%
$86,725 CSL Enters Agreement on Sale of JRH 19 Jan 2005 8:30AM $32.150 $180.720 risen by 462.12%

1151 - 1175 of 1187 results

Page 47 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.